The use of monoclonal antibodies (mAbs) as COVID-19 pre-exposure prophylaxis (PrEP) for immunocompromised patients with haematological malignancies in Germany
Patients with haematological malignancies (HM) are particularly vulnerable to severe outcomes from COVID-19, with mortality rates reaching up to 34% in this patient group following COVID-19 infection (1). Although COVID-19 vaccines have been widely effective in reducing severe outcomes in the general population, patients with haematological malignancies often have limited immune responses to vaccination, even Read More >